Yes—on July 13, 2026, the FDA approved a subcutaneous autoinjector version of lecanemab (brand name LEQEMBI IQLIK) as a *starting* dose for early Alzheimer's disease. That makes lecanemab the first Alzheimer's drug patients can both begin and continue at home, according to the Biogen and Eisai announcement.
Lecanemab is an antibody that clears amyloid-beta, a sticky protein that builds up in the brains of people with Alzheimer's. Until now, patients had to sit through hour-long clinic infusions to start treatment. This approval shifts that first phase to a quick weekly injection you can give yourself or have a caregiver administer.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- FDA Leqembi prescribing information (label) — Use this primary source to review the underlying data.
- Read the official guidance from Eisai — Use this primary source to verify the official guidance.
Table of Contents
- What exactly did the FDA approve?
- Who qualifies for this treatment?
- The safety warning you can't skip
- What at-home dosing does and doesn't change
- Frequently Asked Questions
What exactly did the FDA approve?
The FDA cleared the autoinjector for the *initiation* phase—the treatment's opening stretch. The approved regimen is 500 mg once weekly, delivered as two 250 mg injections that each take about 15 seconds, per Pharmacy Times. This builds on an earlier step.
In August 2025, the FDA had already approved the same autoinjector for weekly *maintenance* dosing—360 mg once weekly after 18 months of treatment, as Eisai reported. The 2026 action fills the remaining gap, so both the start and the continuation of therapy can now happen outside a clinic. The approval rests on the Phase 3 Clarity AD trial, which showed the under-the-skin autoinjector reached drug levels and effects comparable to the original IV form.
Who qualifies for this treatment?
The eligibility rules did not change with the new delivery method. Lecanemab is approved only for people in the earliest stages of Alzheimer's, and a diagnosis has to be confirmed before treatment begins.
You may be a candidate if you meet these conditions, based on the FDA prescribing label: The drug is not approved for later-stage disease, and there is no evidence it helps at those stages. This is a targeted therapy for people caught early, not a general dementia treatment.
- You have mild cognitive impairment or mild-dementia-stage Alzheimer's.
- Amyloid-beta buildup is confirmed by a PET scan or spinal fluid (CSF) test.
- You have not progressed to moderate or severe Alzheimer's.
The safety warning you can't skip
At-home dosing does not remove the medical oversight lecanemab requires. The drug carries a boxed warning—the FDA's strongest—for ARIA, or amyloid-related imaging abnormalities. ARIA covers two problems the label flags: brain swelling (ARIA-E) and small brain bleeds (ARIA-H).
These are often silent, causing no symptoms, but they can occasionally become serious or life-threatening. That is why patients need regular MRI scans to catch problems early, even while injecting at home. Doctors also recommend a genetic test for APOE ε4 before starting. People who carry two copies of this gene variant face a higher ARIA risk, and knowing your status helps your care team weigh the decision and plan monitoring.
What at-home dosing does and doesn't change
The convenience is real. Instead of traveling for infusions, a patient or trained caregiver can give a weekly injection in about 15 seconds per dose. That can ease the burden on families and free up clinic time.
But "at home" does not mean "on your own." Lecanemab remains a prescription drug that requires a confirmed diagnosis and ongoing clinician oversight, as BioArctic notes. Your neurologist still orders the scans, tracks side effects, and decides whether treatment continues. If you want to explore this option, a few practical steps help: The U.S. launch of the initiation autoinjector is planned for late August 2026, so ask your care team about timing and insurance coverage in your area.
- Ask your neurologist whether your diagnosis meets the amyloid-confirmed, early-stage criteria.
- Request APOE ε4 testing to understand your ARIA risk before starting.
- Confirm the MRI monitoring schedule and who will read the scans.
- Ask who trains you or your caregiver on the autoinjector technique.
Frequently Asked Questions
Can I inject lecanemab completely on my own without a doctor?
No. You or a caregiver can give the injection at home, but it stays a prescription drug needing a confirmed diagnosis, MRI monitoring, and clinician oversight.
How is the at-home dose different from the old infusions?
The starting dose is now 500 mg weekly as two 15-second injections under the skin, instead of hour-long IV infusions in a clinic.
Why do I still need MRI scans at home?
To monitor for ARIA—brain swelling or small bleeds that are often symptom-free but can turn serious without early detection.
